Zacks: Brokerages Anticipate Prestige Consumer Healthcare Inc (NYSE:PBH) Will Announce Quarterly Sales of $221.89 Million

Wall Street analysts expect Prestige Consumer Healthcare Inc (NYSE:PBH) to announce sales of $221.89 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Prestige Consumer Healthcare’s earnings, with the lowest sales estimate coming in at $220.00 million and the highest estimate coming in at $224.80 million. Prestige Consumer Healthcare reported sales of $232.15 million in the same quarter last year, which indicates a negative year-over-year growth rate of 4.4%. The firm is scheduled to announce its next earnings results before the market opens on Thursday, August 6th.

On average, analysts expect that Prestige Consumer Healthcare will report full year sales of $946.61 million for the current fiscal year, with estimates ranging from $932.66 million to $956.70 million. For the next financial year, analysts anticipate that the company will post sales of $957.38 million, with estimates ranging from $946.42 million to $966.80 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Prestige Consumer Healthcare.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.08. The firm had revenue of $251.20 million during the quarter, compared to analysts’ expectations of $239.65 million. Prestige Consumer Healthcare had a net margin of 14.77% and a return on equity of 13.33%. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.72 earnings per share.

A number of research firms have commented on PBH. TheStreet upgraded Prestige Consumer Healthcare from a “c” rating to a “b-” rating in a research note on Thursday, May 7th. Sidoti raised Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Monday, June 29th. ValuEngine lowered Prestige Consumer Healthcare from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 2nd. TD Securities boosted their target price on Prestige Consumer Healthcare from $90.00 to $97.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Finally, Jefferies Financial Group downgraded Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday, April 14th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $65.43.

In related news, CEO Ronald M. Lombardi sold 29,593 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $40.00, for a total transaction of $1,183,720.00. Following the completion of the transaction, the chief executive officer now directly owns 154,630 shares in the company, valued at $6,185,200. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the stock. Stifel Financial Corp lifted its holdings in Prestige Consumer Healthcare by 8.1% in the fourth quarter. Stifel Financial Corp now owns 8,455 shares of the company’s stock worth $341,000 after buying an additional 635 shares during the period. UBS Group AG raised its stake in Prestige Consumer Healthcare by 89.2% during the fourth quarter. UBS Group AG now owns 107,370 shares of the company’s stock worth $4,349,000 after purchasing an additional 50,635 shares during the period. Bank of New York Mellon Corp raised its stake in Prestige Consumer Healthcare by 3.4% during the fourth quarter. Bank of New York Mellon Corp now owns 688,934 shares of the company’s stock worth $27,902,000 after purchasing an additional 22,779 shares during the period. Jane Street Group LLC purchased a new position in Prestige Consumer Healthcare during the fourth quarter worth about $483,000. Finally, AQR Capital Management LLC raised its stake in Prestige Consumer Healthcare by 67.8% during the fourth quarter. AQR Capital Management LLC now owns 11,923 shares of the company’s stock worth $483,000 after purchasing an additional 4,817 shares during the period.

Shares of NYSE:PBH traded down $0.39 during mid-day trading on Tuesday, reaching $37.19. 357,825 shares of the stock were exchanged, compared to its average volume of 315,282. The company has a quick ratio of 1.67, a current ratio of 2.44 and a debt-to-equity ratio of 1.50. The company has a market cap of $1.87 billion, a P/E ratio of 13.38, a P/E/G ratio of 3.11 and a beta of 0.80. Prestige Consumer Healthcare has a one year low of $27.40 and a one year high of $46.12. The stock’s 50 day simple moving average is $38.20 and its 200-day simple moving average is $39.22.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.

See Also: What is the price-sales ratio?

Get a free copy of the Zacks research report on Prestige Consumer Healthcare (PBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.